Nasdaq

QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy

QIAstat-Dx syndromic testing system can differentiate novel coronavirus from 20 other respiratory targets Requires less than one minute for sample preparation and delivers results in about one hour ...
Business Insider

New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment

REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...
Seeking Alpha

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
Morningstar

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small ...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer Test will ...
Nasdaq

TMO Receives FDA Approval for Oncomine Dx Target Test

Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Business Wire

QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has begun shipments to the United States of its new QIAstat-Dx ...